N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-1-benzopyran-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide

• ChemBase编号: 72830
• 分子式: C22H26N4O3
• 平均质量: 394.46684
• 单一同位素质量: 394.20049071
• SMILES: c1cc(c2c(c1)OCC[C@H]2Nc1cc(cn2c1nc(c2)C)C(=O)N(CCO)C)C
• Canonical SMILES: OCCN(C(=O)c1cc(N[C@@H]2CCOc3c2c(C)ccc3)c2n(c1)cc(n2)C)C
• InChI: InChI=1S/C22H26N4O3/c1-14-5-4-6-19-20(14)17(7-10-29-19)24-18-11-16(22(28)25(3)8-9-27)13-26-12-15(2)23-21(18)26/h4-6,11-13,17,24,27H,7-10H2,1-3H3/t17-/m1/s1
• InChIKey: YBHKBMJREUZHOV-QGZVFWFLSA-N

名称和登记号

名称

• IUPAC标准名: N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-1-benzopyran-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide
• IUPAC传统名: N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-1-benzopyran-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide
• 别名: 8-[[(4R)-3,4-Dihydro-5-methyl-2H-1-benzopyran-4-yl]amino]-N-(2-hydroxyethyl)-N,2-dimethylimidazo[1,2-a]pyridine-6-carboxamide; N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide; PF 3716556; PF-03716556; PF-3716556; PF-03716556; PF 3716556; [N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide]; PF-03716556

登记号

• CAS号: 928774-43-0
• MDL号: MFCD19690947
• PubChem SID: 162037751
• PubChem CID: 25134521

理论计算性质

• Acid pKa: 15.574108
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): 0.15962853
• LogD (pH = 7.4): 0.9624813
• Log P: 1.0000132
• 摩尔折射率: 114.5694 cm^3
• 极化性: 42.00518 Å^3
• 极化表面积: 79.1 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; DMSO: ≥10 mg/mL; Methanol
• 外观: Light Tan Solid; white to tan powder
• 熔点: 143-145°C

安全信息

• 保存条件: -20°C; Refrigerator
• 德国WGK号: 3
• 保存温度: 2-8°C

药理学性质

• 作用靶点: ATPase

产品相关信息

• 纯度: ≥98% (HPLC)
• 成盐信息: Free Base
• Empirical Formula (Hill Notation): C22H26N4O3

详细说明

Selleck Chemicals - S2222

Research Area: Cancer
Biological Activity:
PF-03716556 is a potent, and selective acid pump antagonist with pIC50 of 6.026 ± 0.112, 6.038 ± 0.039 and 6.009 ± 0.209 at pH 6.4 for the inhibition of H+, K+-ATPase activity of porcine, canine and human ion-leaky membrane vesicles, respectively.PF-03716556 is used for the treatment of gastroesophageal reflux disease. PF-03716556 is highly selective for H+, K+-ATPase in vitro. PF-03716556 displays no activity at Na+, K+-ATPase. PF-03716556 inhibits gastric acid secretion in rat and dog models. PF-03716556 has no species differences among the porcine, canine and human enzymes. PF-03716556 produced greater inhibition than revaprazan in both the in vitro (ion-tight assay) and in vivo conditions. PF-03716556 offers long-lasting and maximal efficacy within 30 min of a single dosing with responses that are maintained for at least 5 days of repeated dosing with no signs of tolerance. PF-03716556 did not exhibit any biologically relevant activity against any of the tested more than 50 (e.g., adenosine receptor) receptors, ion channels, or enzymes expressed in naïve tissues, cell lines and transfectants. [1]References on PF 3716556[1] J Pharmacol Exp Ther., 2009 Feb, 328(2):671-9.

Sigma Aldrich - PZ0155

Biochem/physiol Actions
potent, selective and reversible acid pump antagonist (H, K-ATPase)
Legal Information
Sold for research purposes under agreement from Pfizer Inc.

Toronto Research Chemicals - P293980

A novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.

参考文献

• Mori H et al. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
• Sachs, G., et al.: J. Biol. Chem., 251, 7690 (1976)
• Wallmark, B., et al.: J. Biol. Chem., 262, 2077 (1976)
• Keeling, D., et al.: Biochem. Pharmacol., 37, 2231 (1976)
• Robinson, M., et al.: Drugs, 63, 2739 (1976)